The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the "real world" daily practice as compared with the other drug-eluting stents.
Patients ≥ 19 years old
Patients receiving Synergy XD stent(s) or Synergy Megatron™ stent(s).
The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Patients with a mixture of other drug-eluting stents (DESs)
Terminal illness with life-expectancy ≤1 year.
Patients with cardiogenic shock
Patients with Synergy XD stent or Synergy Megatron™ stent
Cohort
Prospective
Synergy XD stent or Synergy Megatron™ Stent
DevicePercutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
The composite event rate of death, non-fatal myocardial infarction, or target vessel revascularization
A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.
The event rate of all death
The event rate of cardiac death
The event rate of myocardial infarction
The composite event rate of death or myocardial infarction
Click on the lead sponsor to view all of their trials.
Jung-min Ahn
Lead sponsor
Asan Medical Center
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator
